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Abstract 1 
Background: There is a considerable global burden of invasive group B streptococcal (GBS) 2 
disease. Vaccines are being developed for use in pregnant women to offer protection to 3 
neonates. 4 
Objective: To estimate the potential impact and cost-effectiveness of maternal immunisation 5 
against neonatal and maternal invasive GBS disease in the UK.  6 
Methods: We developed a decision-tree model encompassing GBS-related events in infants 7 
and mothers, following a birth cohort with a time horizon equivalent to average life 8 
expectancy (81 years). We parameterised the model using contemporary data from disease 9 
surveillance and outcomes in GBS survivors. Costs were taken from NHS sources and 10 
research studies. Maternal immunisation in combination with risk-based intrapartum 11 
antibiotic prophylaxis (IAP) was compared to the current standard practice of risk-based IAP 12 
alone from an NHS and Personal Social Services (health-provider) perspective. We estimated 13 
the cases averted and cost per QALY gained through vaccination. One-way sensitivity 14 
analysis, scenario analysis and probabilistic sensitivity analysis were performed. 15 
Results: An effective maternal immunisation programme could substantially reduce the 16 
burden of GBS disease. The deterministic analysis estimated the threshold cost-effective 17 
price for a GBS vaccine to be £54 per dose at £20,000 /QALY (£71 per dose at £30,000 18 
/QALY). Results were most sensitive to assumptions on disease incidence, sequelae rate and 19 
vaccine efficacy. Probabilistic analysis showed 90.66% of iterations fell under the £30,000 20 
threshold at a vaccine price of £55. Inclusion of modest prevention of stillbirths and/or, 21 
preterm births, carer health impacts, maternal GBS deaths and 1.5% discounting improved 22 
cost-effectiveness compared to the base case. Lowering vaccine strain coverage made the 23 
vaccine less cost-effective. A key limitation is that the properties of the final GBS vaccine are 24 
unknown. 25 
Conclusions: Maternal GBS immunisation is expected to be cost-effective, even at a 26 
relatively high vaccine price. 27 
Keywords: Group B Streptococcus; vaccine; infant; pregnancy; infectious disease; cost-28 
effectiveness analysis 29 
 30 
Introduction 31 
In the UK, group B Streptococcus (GBS; Streptococcus agalactiae) is a leading cause of 32 
meningitis and septicaemia in babies up to 3 months of age. A recent national prospective 33 
study showed GBS was responsible for half of all neonatal meningitis cases [1]. Invasive 34 
infant GBS disease has a case fatality rate of 5-10% in the UK [1–3], despite the availability 35 
of sophisticated neonatal intensive care. Up to 50% of GBS meningitis survivors have 36 
adverse neurodevelopmental outcomes [4]. GBS is also implicated as a cause of stillbirth 37 
[5,6], pre-term birth [6,7] and maternal sepsis [6,8]. 38 
GBS is part of the natural flora of the human gastrointestinal and genitourinary tracts. 39 
Asymptomatic carriage is common, with 20% of pregnant women in developed countries 40 
carrying GBS rectovaginally [9]. Around 50% of infants born to colonised mothers will 41 
become colonised and 1%  will develop GBS disease [7]. Because maternal colonisation is a 42 
necessary stage in the disease process, at least for early onset disease (defined as <7 days of 43 
age), intervention strategies have, to date, focussed on prophylactic antibiotics for women in 44 
labour targeted on the basis of antenatal screening results and/or identified risk factors [10]. 45 
The incidence of GBS disease has increased in the UK since 2004 [1,11]; enhanced 46 
surveillance studies from the British Paediatric Surveillance Unit (BPSU) reported incidence 47 
of 0.72 per 1000 livebirths in 2004 [3] and 0.97 per 1000 livebirths in 2015 [2]. This increase 48 
is despite the UK prevention strategy of risk factor-based intrapartum antibiotic prophylaxis 49 
(IAP) [12]. The UK has not adopted universal antenatal screening because it is not clear 50 
whether the benefits of screening outweigh the harms for the majority of pregnant women 51 
[13].  Maternal immunisation strategies offer promise for the prevention of infant GBS 52 
disease without reliance on widespread antibiotic use and several vaccine candidates are in 53 
development [14]. 54 
Any new vaccine being considered for introduction into the UK immunisation programme 55 
must be supported with evidence of cost-effectiveness. A previous study [15] examined the 56 
cost-effectiveness of interventions against infant GBS disease in the UK, including maternal 57 
immunisation. This analysis emphasised that further research should prioritise the realisation 58 
of a GBS vaccine, although at this time vaccination was still a distant prospect. Other studies 59 
on the cost-effectiveness of GBS vaccines have been published more recently, including a 60 
study exploring the South African case [16], a study in sub-Saharan Africa [17] and two 61 
based in the USA [18,19]. The aim of this paper is to estimate the potential cost-effectiveness 62 
of GBS vaccine in the current UK context in order to inform both vaccine development and 63 
decision-making once a vaccine is licensed.   64 
 65 
Methods 66 
Model description 67 
A static decision tree model was developed to account for infant GBS disease and long-term 68 
health outcomes, including death, among an annual cohort of UK livebirths (Error! 69 
Reference source not found.). Maternal GBS disease was estimated separately based on the 70 
incidence of disease among maternities (excluding miscarriages). Stillbirths were included in 71 
the estimation of vaccination costs, however, the potential impact of the vaccine on the 72 
prevention of both stillbirths and preterm births was only explored in scenario analysis. 73 
The cohort of livebirths was assumed to be homogenous and was based on 2014 data 74 
reporting 776,352 livebirths in the UK [20–22]. Infants were followed over their lifetime to 75 
enable the inclusion of health outcomes and healthcare costs over this period. The adopted 76 
time horizon was the life expectancy of survivors with no or mild sequelae, which was 81 77 
years [23]. There were 3,563 stillbirths in the UK in 2014 [20,24,25] and these were included 78 
in the estimation of maternal immunisation costs (vaccine purchase and administration). 79 
 80 
Figure 1.Diagram of decision tree model for base case scenario. The structure of the model remains 81 
the same for both strategies; risk factor-based IAP and maternal immunisation with risk factor-based 82 
IAP. Incremental health benefits of the latter strategy were estimated for the annual livebirths 83 
population (776,352 in 2014 data) with vaccination costs estimated for both livebirths and stillbirths 84 
(3,563 in 2014). The potential impact of strategies on maternal disease (all maternities excluding 85 
miscarriage) is estimated separately. 86 
 87 
The current prevention strategy against infant GBS disease within the UK is one of risk 88 
factor-based IAP. The risk factors are a previous baby with GBS disease, maternal GBS 89 
carriage discovered during pregnancy, preterm birth, prolonged rupture of membranes, 90 
suspected maternal intrapartum infection and pyrexia [26]. Assuming that vaccinated 91 
pregnant women will still be provided with IAP in the presence of risk factors, we estimated 92 
the incremental cost-effectiveness of a maternal immunisation strategy in combination with 93 
risk factor-based IAP using the current standard practice of risk factor-based IAP alone as a 94 
comparator. For this reason, any savings that may arise through reduced antibiotic use and 95 
associated care were ignored; making our results more conservative. The model choice was 96 
based on the assumption that a GBS vaccine will not affect colonisation [27,28] and that 97 
maternal immunisation will offer protection for only a single pregnancy which is also a 98 
conservative approach in regard to the benefits of a GBS vaccine. 99 
The model was computationally implemented in R using standard packages, and used to 100 
investigate costs and benefits of maternal immunisation from the perspective of the NHS and 101 
Personal Social Services (health provider). We followed standard methods on cost-102 
effectiveness analysis; the Joint Committee on Vaccination and Immunisation (JCVI), who 103 
make vaccine recommendations in the UK, in principle follow NICE methodology although 104 
more specific detail on dealing with uncertainty is given [29]. 105 
Parameter values - Disease 106 
The latest available UK data on GBS disease and sequelae were used to parameterise the 107 
model. GBS disease incidence was informed by the most recent BPSU enhanced surveillance 108 
study for infants up to 3 months of age [2]. Case fatality rates were based on the same source, 109 
while UK-wide data on livebirths and stillbirths were obtained from the Office for National 110 
Statistics [22,30–33]. Parameter estimates are presented in Table 1. 111 
Preliminary data from a follow-up study of survivors of GBS disease were used to estimate 112 
disease after-effects (Heath et al unpublished). Survivors were followed-up 3 to 5 years after 113 
recovery with quality of life assessments and neurodevelopmental outcomes. Sequelae 114 
stratified by severity (mild, moderate and severe) along with quality-adjusted life year 115 
(QALY) loss for each severity group were estimated (Appendix 1). Life expectancy data for 116 
the general population [23] and GBS survivors [52–54](Appendix 1) were included in the 117 
model to encompass the full lifetime impact of GBS disease on cases.  118 
Table 1. Base case parameter values of deterministic analysis and parameter distributions of probabilistic sensitivity analysis. 119 
Parameter Base value Distribution Source 
Infant disease    
GBS disease incidence 0.97/1,000 livebirths unif(0.000873,0.001067) [2] 
EOD incidence 0.58/1,000 livebirths unif(0.000522,0.000638) [2] 
LOD incidence  0.39/1,000 livebirths unif(0.000351,0.000429) [2] 
Mortality rate  
0.044 (EOD), 0.076 
(LOD) 
unif(0.0396,0.0484) (EOD), 
unif(0.0684,0.0836) (LOD) 
[2] 
Severe sequelae rate 
0.055 (EOD), 0.053 
(LOD) 
unif(0.0495, 0.0605) (EOD), unif(0.0477, 
0.0583) (LOD) 
Based on Heath et al unpublished 
Moderate sequelae rate 
0.096 (EOD), 0.092 
(LOD) 
unif(0.0864, 0.1056) (EOD), unif(0.0828, 
0.1012) (LOD) 
Based on Heath et al unpublished 
Mild sequelae rate 
0.341 (EOD), 0.330 
(LOD) 
unif(0.3069, 0.3751) (EOD), unif(0.297, 
0.363) (LOD) 
Based on Heath et al unpublished 
Quality of life loss for sequelae cases 
 0.299 (severe), 0.056 
(moderate), 0.002 (mild) 
Beta(7.475,17.525) (severe), Beta(2.8,47.2) 
(moderate), Beta(2,998) (mild) 
Based on Heath et al unpublished 
Life expectancy in years (GBS sequelae) 
25 (severe), 71 
(moderate), 81 (mild) 
Triangular(11, 25, 43) (severe), Triangular(43, 
71, 81) (moderate) 
Based on: severe [34], moderate- 
[23,34], mild –[23,34] 
Disease diagnoses 
EOD: 63.0% (sepsis), 
3.1% (meningitis), 23.9% 
(pneumonia) 
Not tested [2] 
LOD: 63.3% (sepsis), 
34.9% (meningitis), 1.8% 
(pneumonia) 
Not tested [2] 
Maternal disease    
Maternal GBS disease incidence 0.27/1,000 maternities unif(0.000243, 0.000297) Based on [35] 
General population    
Life expectancy (general population) 81  [23] 
Livebirths (yearly) 776,352  [20–22] 
Stillbirths (yearly) 3,563  [20,24,25] 
Vaccine    
Vaccine uptake rate 0.6 Beta(3,2) [36] 
Vaccine efficacy 0.85 unif(0.6,1) Based on [37,38] 
Vaccine strain coverage (pentavalent) 0.962 Triangular(0.8658,.962, 1) [2] 
Vaccine adverse reaction rate 
0.01 (GP) and 0.003 
(anaphylaxis) 
Beta(1,99) (GP) and Beta(3,997) (anaphylaxis) 
GP – assumed, no data available 
Anaphylaxis - [39] 
Economic costs (£)    
Healthcare costs per infant case (first 2 
years) 
11,670.99 (EOD) and 
11,993.51 (LOD) 
Gamma(24,scale=500)  
Resource usage- [40], costs - 
[41,42] 
Annual long-term care costs per case 
6,000 (severe), 3,000 
(moderate), 1,000 (mild) 
Triangular(4000,6000,32000) (severe), 
Triangular(2000,3000,4000) (moderate), 
Triangular(500,1000,2000) (mild) 
Based on [43–45] 
Maternal disease costs 2,475.79 Triangular(367.08, 2475.79, 7341.59) Based on [35] 
Vaccine administration cost per dose 9.80 Not tested [46] 
Vaccine adverse reaction cost 
42.42 (GP) and 468.55 
(anaphylaxis) 
Gamma(220, scale=2.13) (anaphylaxis) Based on [41,42] 
Award per litigation claim 563,241.27 Gamma(5.63,scale=100043) 
Based on: base case -[47], 
distribution- [44,47–50] 
Litigation    
Rate of successful litigation claims per 
infant GBS case 
0.0137 unif(0.011,0.0339)   Combination of [2,47–51] 
Litigation claim delay 2 years unif(1,6) [48] 
Number of payments of litigation award 20 unif(15,25) [44] 
Proportion of successful litigation cases 
being fatalities 
0.379 unif(0.3411, 0.4169) [48] 
Sources provided for base case values, while wherever possible parameter distributions were also informed by data. More information is available in 120 
Appendix 1. GBS: group B Streptococcus, EOD: early-onset disease, LOD: late-onset disease, GP: general practitioner121 
Maternal GBS infections were identified by linking laboratory confirmed cases of invasive 122 
disease (i.e. GBS isolated from a sterile site) reported to PHE through routine surveillance in 123 
England in 2014 to hospital admissions captured through NHS Digital Hospital Episode 124 
Statistics (HES). Pregnancy or recent childbirth (within 6 weeks of diagnosis) was identified 125 
in HES through assessment of maternity fields, clinical ICD-10 codes, admission method, 126 
medical specialty or surgical procedure codes [35]. Maternal GBS disease parameter values 127 
were based on HES data on maternal GBS sepsis (Appendix 1) and maternal life expectancy 128 
was based on the National Life Tables for the United Kingdom [55]. 129 
Parameter values – Costs 130 
All costs were in 2015 £GBP, with estimates from previous years inflated using Hospital and 131 
Community Health Services (HCHS) pay and prices index [56]. 132 
Healthcare costs for infant GBS cases in the first two years of life were based on resource 133 
utilisation data by Schroeder et al [40], in combination with NHS Reference data [42] and 134 
Unit Costs of Health and Social Care [41]. Details on parameter estimates are given in 135 
Appendix 1. Data on long-term sequelae costs are scarce; only one study reporting estimates 136 
for healthcare costs for very severe meningitis and sepsis sequelae was identified [43]. 137 
Litigation costs were sought from the NHS Litigation Authority through a Freedom of 138 
Information Request; the available data, however, were not disease-specific (Appendix 1). 139 
Estimates used in this study were the result of data synthesis from a number of different 140 
sources (Appendix 1). Furthermore, the model includes litigation costs only beyond the 141 
product of lost QALYs and ceiling ratio of cost per QALY gained, following current 142 
Department of Health practice (Peter Grove personal communication, 24 October 2016). 143 
Healthcare costs for maternal GBS disease were derived from the corresponding hospital 144 
admission record during which the laboratory diagnosis was made. An average cost per 145 
maternal disease case was calculated weighing the relevant HRG codes recorded in HES 146 
according to their frequency (Appendix 1). 147 
Potential adverse effects of vaccination were also considered. These included both mild 148 
effects requiring a GP visit and more serious adverse effects such as anaphylaxis (Appendix 149 
1).   150 
Parameter values - Vaccine 151 
The base case scenario considered immunisation of pregnant women in the UK with a 152 
pentavalent vaccine (serotypes Ia, Ib, II, III and V). Women of at least 24 weeks of gestation 153 
would be offered the vaccine against GBS. Strain coverage by such a vaccine was estimated 154 
to be 96.2% based on the latest surveillance data [2] (Appendix 1). Vaccine uptake was set at 155 
60% based on information from the pertussis maternal immunisation programme [57]. Data 156 
on vaccine efficacy are not currently available so our assumption of 85% was based on 157 
reported vaccine efficacy for other conjugate vaccines [37,38] (Appendix 1). Vaccine price is 158 
also currently unknown. Here, we tested different vaccine prices with the aim of identifying 159 
those for which a GBS vaccine would be cost-effective.  160 
The size of the maternities cohort (excluding miscarriages) in combination with the vaccine 161 
uptake rate means an estimated 467,949 immunisations will occur annually in the UK. The 162 
costs of purchasing and administering the vaccine for this population was estimated in the 163 
model. 164 
Parameter values - Discounting 165 
Following JCVI guidelines [29] future costs and health outcomes were discounted at 3.5% 166 
and a threshold of £20,000 per QALY gained was applied. A threshold of £30,000 per QALY 167 
gained was also explored as well as an alternative scenario of £15,000 per QALY at 1.5% 168 
discounting for both future costs and health outcomes. 169 
 170 
Sensitivity Analysis 171 
Through univariate sensitivity analysis, we explored the effect of individual parameters on 172 
the vaccine impact and vaccine cost-effectiveness, while we identified the threshold cost-173 
effective vaccine price for the base parameter values. Parameters were varied by ±50%, with 174 
some exceptions applying for cases where this variation was beyond their 175 
maximum/minimum possible values. We also explored the cumulative effect of groups of 176 
parameters - irrespective of disease onset or sequelae severity (overall values of: disease 177 
incidence, fatality rate, sequelae rate and cost per sequelae case and combination of: overall 178 
disease incidence and vaccine efficacy).  179 
Scenario analysis was used to test assumptions excluded from the base case scenario. 180 
Prevention of stillbirth and/or premature birth are important potential advantages of maternal 181 
immunisation over the current practice of risk factor-based IAP, however, such benefits are 182 
currently hypothetical. We tested the potential impact of a GBS vaccine on prevention of 183 
stillbirth and premature birth, both in combination and individually. In the investigation of 184 
stillbirth prevention, we accounted for averted cases having the life expectancy of healthy 185 
survivors. For preterm births, we accounted for the relevant healthcare costs. We also 186 
considered other scenarios offering additional health outcomes, including prevention of 187 
maternal deaths and effect of disease on the health of carers (predominantly parents; recent 188 
economic evaluation studies have accounted for the impact of disease on the quality of life of 189 
carers [41–43]). A scenario of decreased vaccine strain coverage, with a trivalent GBS 190 
vaccine used instead of the base case scenario assumption of a pentavalent vaccine was also 191 
explored. Parameters for all scenarios are available in Appendix 1 (Table 9). 192 
Furthermore, Monte Carlo probabilistic sensitivity analysis of 5,000 iterations was carried 193 
out.The choice of parameter intervals and distributions (Table 1) was informed by data where 194 
possible. Beta distributions were selected for parameters bounded between zero and one and 195 
gamma distributions for parameters describing costs. Exceptions were made for parameters 196 
which required integer numbers, parameters where detailed data were available and 197 
parameters where specific distinctions between the intervals describing sequelae of varying 198 
severity (mild, moderate, severe) were needed. In these cases, uniform or triangular 199 
distributions were selected. 200 
 201 
Results 202 
Deterministic Model Results 203 
In the base case scenario, we estimated that maternal GBS immunisation will prevent 369 204 
cases of GBS in infants annually, including 179 cases with sequelae. Twenty one infant 205 
deaths will be averted and 103 maternal cases will also be avoided. In total, 563 life years 206 
will be gained from averted infant deaths and 232 from averted infant sequelae which would 207 
have resulted in premature mortality. The total gain in QALYs from infant disease will be 208 
870. Exploration of the base case scenario showed the maximum vaccine price for which 209 
immunisation remains cost-effective to be £54 per vaccine dose at £20,000/ QALY gained. 210 
The maximum vaccine price when a threshold of £30,000 per QALY was considered was 211 
£71. 212 
A variety of different vaccine prices were explored and the changing cost per QALY gained 213 
is presented in Appendix 2 (Table 1). For our base case scenario, a vaccine price of £54 per 214 
dose was adopted. The gross costs of vaccination were estimated at £30.7 million, which 215 
includes the costs of buying and administering the vaccine. The net cost of vaccination to the 216 
NHS and the PSS will be approximately £17.4 million, accounting for savings from the 217 
reduced burden of disease. 218 
The cost per QALY gained is £19,953, the cost per infant case prevented £46,987 and the 219 
cost per death averted £826,284. The results of the base case scenario are summarised in 220 
Table 2. 221 
Sensitivity analysis results 222 
One-way sensitivity analysis identified a number of highly influential parameters (Error! 223 
Reference source not found.), with overall disease incidence and vaccine price having the 224 
biggest effect on model results. Vaccine uptake did not alter the incremental cost-225 
effectiveness of the maternal immunisation strategy with risk factor-based IAP in comparison 226 
with risk factor-based IAP alone, with both costs and health effects being multiples of this 227 
rate and cost per QALY gained remaining unchanged.  228 
Scenario analysis 229 
Several scenarios were explored as alternatives to the assumptions of the base case 230 
(Appendix 2, Table 2). Potential prevention of stillbirths and/ or preterm births by the GBS 231 
vaccine, for instance, would increase its added benefits, making it more cost-effective. With a 232 
theoretical 1% of stillbirths assumed to be vaccine-preventable, the maximum cost-effective 233 
vaccine price was £94 (£54 per dose in the base case). A similar percentage of vaccine-234 
preventable (surviving) preterm births had a lesser impact, with the maximum cost-effective 235 
price rising to £59. A combination of both resulted in a maximum cost-effective price of 236 
£100. 237 
Table 2. Deterministic model results for base case scenario. 238 
Health outcomes 
Risk factor-based 
IAP alone 
(current strategy) 
Maternal 
immunisation 
with risk factor-
based IAP 
(proposed 
strategy) 
Incremental 
benefits of 
proposed 
immunisation 
strategy 
Infant disease cases 753 384 -369 
Infant cases with sequelae  365 186 -179 
Infant deaths 43 22 -21 
Maternal disease cases 210 107 -103 
Life-years lost to infant deaths 
(discount rate of  3.5% applied) 
1,148 585 -563 
Life-years lost to infant sequelae 
which would have resulted in 
premature mortality (discount rate 
of  3.5% applied) 
473 241 -232 
QALY loss (discount rate of  
3.5% applied) 
1,773 903 -870 
    
Costs (£ millions) 
Risk factor-based 
IAP alone 
(current strategy) 
Maternal 
immunisation 
with risk factor-
based IAP 
(proposed 
strategy) 
Incremental costs 
of proposed 
immunisation 
strategy 
Maternal immunisation - 30.7 30.7 
Infant GBS disease (both short- 
and long-term costs) 
25.2 12.8 -12.4 
Litigation 1.5 0.8 -0.7 
Maternal GBS disease 0.5 0.3 -0.2 
Total 27.2 44.6 17.4 
    
Cost-effectiveness measures   
Incremental cost-
effectiveness of 
proposed 
immunisation 
strategy 
Cost per QALY gained   19,953 
Cost per case prevented   46,987 
Cost per death averted   826,284 
Cost per life-year gained   21,828 
Cohort size: 776,352 livebirths, 3,563 stillbirths. Stillbirths were only included in the estimation of 239 
immunisation costs. Maternal immunisation parameters: vaccine price = £54/dose, vaccine efficacy = 240 
85%, vaccine strain coverage = 96.2%, vaccine uptake rate = 60%. Litigation costs included in the 241 
table exclude those already accounted for through lost QALYs (Department of Health practice). IAP: 242 
intrapartum antibiotic prophylaxis, QALY: quality-adjusted life year, GBS: group B Streptococcus 243 
 244 
 245 
Figure 2. Results of one-way (vaccine price, vaccine efficacy) and multi-way (overall: sequelae 246 
rate, fatality rate, disease incidence and cost per sequelae case) sensitivity analysis. Base value 247 
estimates were varied by ±50% with the exception of vaccine efficacy which was varied by ±0.15 248 
(maximum value = 1). Base case scenario cost per QALY (£19,953) is displayed by the middle line in 249 
each bar. Parameters displayed here are those whose alteration had an impact in the cost per QALY of 250 
at least 20%. The impact of EOD and LOD incidence is presented here in a cumulative way, though 251 
both parameters have an individual effect on the cost per QALY at beyond 20% its base case value 252 
(£19,953). QALY: quality-adjusted life year, EOD: early onset disease, LOD: late onset disease 253 
 254 
To date, no maternal deaths caused by GBS have been reported in the UK [35,58]. 255 
Considering the possibility that some maternal fatalities could occur [59], we accounted for a 256 
maternal fatality rate of 1% among maternal GBS cases. The GBS vaccine was only 257 
marginally more cost-effective in this scenario with the threshold cost-effective price 258 
(rounded to the nearest GBP) remaining the same. 259 
We considered the potential effect of health spillovers for cases with sequelae and for 260 
fatalities in one of the scenarios we explored, adjusting this for those displaced by funding the 261 
intervention [60] (Appendix 1). Results showed the vaccine programme to be more cost-262 
effective, increasing the threshold vaccine price by £6 (Appendix 2, Table 2).  263 
A ‘most favourable’ scenario incorporating all of the above increased the threshold vaccine 264 
price to £107. 265 
The case of a trivalent GBS vaccine (Appendix 1) was explored and compared with the base 266 
case assumption of a pentavalent vaccine (Appendix 2, Table 2). The threshold vaccine price 267 
at £20k/ QALY was £8 less than the pentavalent vaccine. 268 
Finally, an alternative 1.5% discount rate for both future costs and health outcomes with a 269 
£15,000/ QALY threshold scenario was explored to reflect discussions on the appropriate 270 
threshold [61,62]. Comparing the base case results with this scenario, the vaccine became 271 
even more cost-effective (£78 per dose) with the alternative guidelines applied (£54 per dose 272 
in the base case).  273 
Probabilistic sensitivity analysis 274 
Consistency of results for the base case scenario (assuming £54 per dose) was explored in the 275 
probabilistic sensitivity analysis, where parameter distributions were set to reflect estimates’ 276 
variations perceived as realistic. Uncertainty guidelines require at least 90% of iterations to 277 
be under the £30,000 threshold [29]. Of the 5,000 iterations that were run, 92.24% fell under 278 
the £30,000 threshold of cost per QALY gained (Error! Reference source not found.), 279 
while a slightly higher vaccine price of £55 per dose showed 90.66% of iterations below the 280 
£30,000 threshold. Model outcomes were highly dependent on vaccine price Figure 4. 281 
 282 
 283 
 284 
 285 
Figure 3. Monte Carlo probabilistic sensitivity analysis of 33 parameters, 5,000 iterations, for 286 
base case scenario. The incremental cost (£) of the maternal immunisation strategy with risk factor-287 
based IAP comparing with that of risk factor-based IAP alone is plotted in the y axis, with the x axis 288 
displaying the incremental QALYs gained. Of the 5,000 iterations 92.24% fall below the £30,000 289 
ceiling ratio (blue line) of cost per QALY gained and 56.62% below the £20,000 threshold (red line). 290 
QALY: quality-adjusted life year 291 
 292 
 293 
Figure 4. Effect of vaccine price (£) on the percentage of Monte Carlo iterations (total of 5,000) 294 
for which the immunisation strategy is cost-effective (threshold of £30,000 per QALY gained). 295 
Discount rate is 3.5% for both future costs and health outcomes. Vaccine price per dose for the base 296 
case scenario is £54. QALY: quality-adjusted life year 297 
 298 
Investigating the effect of the interplay between vaccine efficacy and overall disease 299 
incidence on the probabilistic sensitivity analysis results, it is evident that uncertainty in the 300 
cost per QALY gained is mainly driven by vaccine efficacy (The cost-effectiveness 301 
acceptability curve is presented in Error! Reference source not found.. The latter exhibits 302 
the changing incremental cost-effectiveness of the maternal immunisation strategy with risk 303 
factor-based IAP in comparison with risk factor-based IAP alone for the base case of 304 
parameter values (vaccine price of £54 per dose), for a changing ceiling ratio of cost per 305 
QALY gained.  306 
 307 
Figure 5. Comparison of overall disease incidence and vaccine efficacy as drivers of vaccine cost-308 
effectiveness, in Monte Carlo probabilistic sensitivity analysis of 5,000 iterations, where other 309 
parameter values remain as in base case scenario. Vaccine price per dose for the base case scenario 310 
is £54. Incremental cost (£) per QALY gained of the maternal immunisation strategy with risk factor-311 
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safe, effective vaccine that can be purchased and administered at a reasonable price. The 361 
proposed new strategy is compared to the current strategy of risk factor-based IAP alone. In 362 
the base case, we estimated that, with 60% coverage, 369 infant cases, 103 maternal cases 363 
and 21 infant deaths could be averted in a single birth cohort. Additional benefit would be 364 
achieved if coverage were closer to the 75% achieved recently in the maternal pertussis 365 
programme [63]. The threshold cost per dose was £54 at £20,000/ QALY; at this price, the 366 
uncertainty rules are also met, with 92.24 % of simulations in the probabilistic sensitivity 367 
analysis falling below £30,000/QALY. Most of the alternative scenarios we investigated 368 
improved the cost-effectiveness of immunisation.  Prevention of stillbirths and/ or preterm 369 
births would increase vaccine cost-effectiveness, while the prevention of maternal deaths 370 
from GBS sepsis would only have a minor impact, as this is considered to be rare. Both a 371 
trivalent and a pentavalent vaccine would be cost-effective, with the latter being clearly more 372 
attractive for both the health system and vaccine manufacturers. Accounting for the health 373 
benefits gained (and displaced) from reducing the strain on carers also makes the vaccine 374 
more cost-effective. The cumulative effect of including all vaccine-favourable scenarios more 375 
than doubles the threshold vaccine price.  376 
Strengths and limitations 377 
The inclusion of the latest UK surveillance data in this study [2] is a major strength. 378 
Moreover, we included preliminary data on outcomes and sequelae among UK infant GBS 379 
survivors from an on-going study, an area previously lacking in evidence. We are conducting 380 
further research on the relation between quality of life and severity of sequelae in infants with 381 
GBS disease. Unlike other studies of the cost-effectiveness of GBS maternal vaccination, we 382 
accounted for maternal disease outcomes, litigation costs and health impact on carers. To the 383 
best of our knowledge, this is the first cost-effectiveness study on GBS considering displaced 384 
health spillover benefits. 385 
A key limitation is that we do not yet know the properties of the vaccine. Vaccine efficacy is 386 
currently unknown; given the experience with other conjugate vaccines, we would expect a 387 
GBS vaccine would demonstrate high efficacy over the course of the infant risk period for 388 
both EOD and LOD but this can only be estimated once a vaccine becomes available. We 389 
considered vaccination to be necessary in each pregnancy, with no enduring protection from 390 
vaccine given in a previous pregnancy. Studies of antibody persistence will be needed to 391 
determine whether this is necessary.  392 
We did not consider any potential impact of maternal immunisation on maternal GBS 393 
colonisation. In one study non-pregnant women who received a GBS conjugate vaccine were 394 
found to have a significantly longer time to first vaginal acquisition than women in the 395 
control group [27], but no clear effect on colonisation was observed in a pregnancy trial with 396 
a different GBS conjugate vaccine [64].  We consider it unlikely that an immunisation 397 
programme targeting only pregnant women would have profound effects on the population 398 
biology of GBS even if a vaccine did influence carriage and so we chose a static decision tree 399 
model rather than a transmission dynamic model. However further research is necessary to 400 
fully understand the implications of a vaccine affecting colonisation, e.g. of vaccine selection 401 
pressure driving serotype replacement.   402 
We did not have good data on the long-term economic cost of sequelae, estimates included in 403 
the model are speculative and results suggest they are influential. This issue could be 404 
addressed through appropriate follow-up studies of GBS survivors (our current follow-up 405 
study addresses prevalence but not cost of outcomes).  406 
We investigated the added benefit of a maternal immunisation strategy where IAP is still used 407 
when pre-defined risk factors are identified. This does not address any potential savings 408 
which accrue if fewer antibiotics are administered and the important but less tangible benefits 409 
of reducing selection pressure which could lead to antibiotic resistance. We did not 410 
investigate other preventive strategies, such as universal screening for GBS colonisation, as 411 
we concentrated on the current UK context.  412 
Finally, we also explored the effect of the healthcare system’s willingness (and ability) to pay 413 
on cost-effectiveness, as a reminder of its influence on the analysis outcomes. We only 414 
considered the health provider’s perspective, following standard NICE methodology and we 415 
did not investigate wider societal costs and benefits. 416 
Comparison with other studies 417 
A previous cost-effectiveness study on GBS disease in the UK [53] showed that a 418 
combination of vaccination with IAP for some maternal risk groups was amongst the most 419 
cost-effective of the tested strategies.  Our analysis uses up-to-date parameter estimates, 420 
including increased incidence, and emphasises the added benefits of vaccination with risk-421 
based IAP, rather than comparing a range of screening options. Other studies on the cost-422 
effectiveness of maternal immunisation have been conducted in South Africa [16]; sub-423 
Saharan Africa [17] and the USA [18,19].  424 
All of these studies concluded that GBS vaccination could be a cost-effective intervention, 425 
but found that disease incidence, vaccine efficacy and vaccine cost were key determinants, 426 
with most of the studies also including fatality rates in this list. The studies from the USA 427 
[18,19] are more directly comparable to our study, as they investigate the added benefit of 428 
vaccination in terms of cost per QALY in a country with sophisticated healthcare. However, a 429 
key difference is that they compared vaccination in combination with screening-based IAP 430 
versus screening based IAP only (the current US standard of care). This prevents a head-to-431 
head comparison, but it does appear that given the current incidence and standards of care, a 432 
UK programme might be more cost-effective than a maternal immunisation programme in the 433 
USA.  In the future, a model comparison exercise to examine the differences in model 434 
assumptions, parameters and results could be of value.  435 
 436 
Conclusion 437 
A strategy of maternal immunisation in combination with risk-based intrapartum antibiotic 438 
prophylaxis against GBS disease in infants up to three months of age is likely to be cost-439 
effective in the UK, offering excellent prospects for reducing the burden of GBS disease. 440 
 441 
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